On September 29, 2025, Dogwood Therapeutics, Inc. announced it had secured a worldwide, royalty free license to develop SP16 for the treatment of cancer related pain and chemotherapy induced neuropathy symptoms from Serpin Pharma. A Phase 1b study of SP16 in Chemotherapy Induced Peripheral Neuropathy (CIPN) that is fully funded by the National Cancer Institute is scheduled to begin patient enrollment in the first half of 2026. This deal expands Dogwood's research pipeline and complements the ongoing development of Halneuron , which is currently in a Phase 2b clinical trial for Chemotherapy Induced Neuropathic Pain (CINP). An interim analysis for that trial is expected in the fourth quarter of 2025.
